Evidence item

The reported DCR is 95.0% with a two-sided 95% confidence interval of 83.5–99.4 in the 40-participant analysis. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25927

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:e5e039c1ff84a003853a2d70ecddfe51593dadaf2f3805b15e0bff67071bd815

The ORR was 55% (22/40; 95% CI 38.5–70.7), exceeding the prespecified Simon two-stage criterion... and the DCR was 95.0% (95% CI 83.5–99.4).